The survival after discontinuation of EGFR-TKIs due to intolerable adverse events in patients with EGFR-mutated non-small cell lung cancer.
John Wen-Cheng ChangChing-Fu ChangChen-Yang HuangCheng-Ta YangChih-Hsi Scott KuoYueh-Fu FangPing-Chih HsuChiao-En WuPublished in: Thoracic cancer (2022)
Patients experiencing intolerable AEs during EGFR-TKI treatment should consider switching to an alternative EGFR-TKI, which increase the survival results as compared to those patients who did not experience intolerable AEs.